The Director, HTA, Value & Evidence (HV&E) – Antivirals will support the strategic goals of the Primary Care Division by driving optimal patient access for Antiviral medicines.

This role directly impacts the ability to achieve business objectives on a global basis by providing strategic guidance and robust evidence development relevant to achieve optimal patient access by demonstrating the value of our Antiviral medicines. The HV&E Director will be responsible for developing and executing against the global evidence generation strategy, including direct oversight of evidence generation activities and dissemination of technical deliverables.

This position will be part of Pfizer’s dynamic Global Access & Value (GAV) team and will have the important role of managing health economics and outcomes research (HEOR) to generate data to support patient access to Antiviral medicines, with a primary focus on pipeline Antiviral assets. Based on the needs of the antiviral franchise, this colleague is expected to work across different geographies as well as on launch or pipeline assets. Flexibility is expected seeing the evolving needs of the antiviral franchise. This position will be working closely with the Antiviral GAV, cross-functional and country teams to foster a culture that promotes innovation and thrives on doing better for Pfizer’s patients and healthcare.

ROLE RESPONSIBILITIES

• Lead the development of the evidence generation strategy to support the value of Antiviral pipeline assets in the Primary Care Divisionin close partnership with the cross-functional matrix team.
• Lead the coordination of input from local country/regional teams on evidence needs and ensure that the input is appropriately incorporated to develop and integrate the evidence strategy to support global market access needs at launch and through lifecycle.
• Lead the design and execution of global HEOR studies (e.g., economic models, network meta-analyses, non-interventional studies) from concept through publication.
• Develop patient-reported outcomes strategy and incorporate humanistic and economic endpoints into clinical trials across all phases of product development to build comprehensive trial-based evidence aligned with overall asset strategy and to ensure global reimbursement and access requirements. Provide strategic input into clinical trial designs (e.g., patient populations, comparators, endpoints) and analysis to enable successful negotiations, reimbursement, and appropriate patient access with global payer and regulatory decision makers.
• Lead the timely development of launch deliverables including value & evidence strategy, global value dossiers/AMCP dossiers, systematic literature reviews, economic models, and innovative tools to successfully support reimbursement and access requirements in conjunction with the regions/countries.
• Partner with internal stakeholders to ensure appropriate customer facing dissemination of HEOR materials per regulatory guidance and internal SOPs.
• Develop strategic partnerships and research collaborations with key external experts, healthcare policy makers, payers, and various academic and community Antiviral settings to support asset strategies.

BASIC QUALIFICATIONS

Candidate demonstrates a breadth of diverse leadership experiences and capabilities including: the ability to influence and collaborate with peers, develop and coach others, oversee and guide the work of other colleagues to achieve meaningful outcomes and create business impact.

• Graduate degree minimum required (e.g. MSc, MPH, PhD)
• 9+ years of experience required with MSc/MPH/MBA degree; 7+ years of experience required with PharmD/PhD in HEOR or relevant related fields (health economics, epidemiology, health services research, or other research-focused public health field)
• Demonstrated in depth understanding of fundamental health services research methods and tools, including health economic modeling, patient-reported outcomes, statistics, and real-world evidence studies including technical and methodological aspects of registries and observational study design, implementation, analysis and interpretation. Capable of independently managing complex non-interventional study projects
• Knowledge and understanding of drug development process
• Excellent interpersonal skills required: ability to understand and respond to multiple internal and external customers
• Excellent oral and written English communication skills
• Demonstrated ability to assess anticipated value for projects/programs to ensure alignment to business priorities and prioritize accordingly
• An “execution mindset” focused on getting things done quickly and simply
• Strong project management abilities (contracting, budgeting, vendor management) essential. Demonstrated ability to manage multiple projects (multitask) involving complex processes, significant budget, competing deadlines and rapidly shifting priorities
• Ability to influence key members of medical, clinical, and commercial teams constructively and without conflict
• Skilled in functioning within a matrix organization where managing through influence
• Organized and detail oriented with the ability to anticipate needs and to work proactively to prioritize & address/resolve
• Change oriented, comfortable responding to unexpected demands with tight timelines; team player

PREFERRED QUALIFICATIONS

• Knowledge and experience in the Infectious Disease therapeutic area
• Experience with HTA organizations such as NICE, CADTH, PBAC, ICER and other HTA groups

Other Job Details:

• Last Date to Apply for Job:November 12th, 2024.
• Position is hybrid and will require to work from site 2 to 3 days per week
• NOT Eligible for Relocation Package
• Ability to travel domestically and international based on business needs